

Remarks**The Restriction Requirement**

Applicants maintain their assertion that the Examiner has over-narrowly restricted examination of the claims. However, in order to expedite prosecution of the case Applicants have narrowed the claims to reflect the Examiner's restriction.

Objection to Claim 50

Applicants have amended the dependency of claim 50 in order to address the objection raised by the Examiner, and thus request that the objection be withdrawn.

Rejection under Section 112


Applicants have amended the definition of R² to address the rejection raised by the Examiner, and thus request that the rejection be withdrawn.

Double Patenting

Claims 1-5, 8, 9, 11-17, 19-21, 24, 30, 31, 33, 34, 36-38, 40, 43, 45, 46 and 48-50 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being allegedly unpatentable over claims 22 and 42 of co-pending Application No. 11/042,398. Without acquiescing to the Examiner's rejection and solely to promote allowance of this case, a terminal disclaimer over any patent granted on U.S. Application No. 11/042,398 is submitted herewith. Thus, applicants request that the rejection be withdrawn.

Respectfully Submitted,

Dated: July 25, 2008



Ronald S. Hermenau, Reg. No. 34,620
Attorney for Applicants
AMGEN INC.
1120 Veterans Boulevard
South San Francisco, CA 94080
Phone: (650) 244-2261
Fax: (650) 244-2392